Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The
international EAACI/GA2
LEN/EuroGuiDerm/APAAACI guideline for the definition, classification,...
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2
LEN/EDF/
WAO guideline for the definition, classification, diagnóstico
and management...
Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium
Internationale Allergologicum (CIA) Update 2020. Int Arch
Allergy Immunol. 2020;181(5):321–333....
Cassano N, Nettis E, Di Leo E, et al. Angioedema associated
with dipeptidyl peptidase-IV inhibitors. Clin Mol Allergy. 2021;
19(1):24. https://doi.org/10.1186/s12948-021-00164-7...
Campbell DJ. Neprilysin Inhibitors and Bradykinin. Front Med
(Lausanne). 2018;5:257. https://doi.org/10.3389/fmed.2018.
00257 PMID: 30283782;...
Santacroce R, D’Andrea G, Maffione AB, et al. The genetics of
hereditary angioedema: a review. J Clin Med. 2021;10(9):2023.
https://doi.org/10.3390/jcm10092023...
Metz M, Vadasz Z, Kocatürk E, et al. Omalizumab updosing in
chronic spontaneous urticaria: an overview of real-world
evidence. Clin Rev Allergy...
Alves F, Calado R, Relvas M, et al. Short courses of ciclosporin
can induce long remissions in chronic spontaneous urticaria. J
Eur Acad Dermatol...
Giménez Arnau AM, Valero Santiago A, Bartra Tomás J, et al.
Therapeutic Strategy according to differences in response to
omalizumab in patients...
Giménez-Arnau AM, Jáuregui I, Silvestre-Salvador JF, Urticaria
Study Group, et al. Consensus on the definition of control and
remission in...
Wedi B. Emerging treatments for chronic urticaria. Expert Opin
Investig Drugs. 2022;31(3):281–290. https://doi.org/10.1080/
13543784.2022.2042513...
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, et al.
Omalizumab for the treatment of chronic inducible urticaria
in 80 patients....
Can PK, Salman A, Hoşgören-Tekin S, et al. Effectiveness of
omalizumab in patients with chronic inducible urticaria: reallife experience from...
